0.8457

9.36% -0.0873

After Hours: .85 0.0043 +0.51%

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $0.8457, with a volume of 839.59K. It is down -9.36% in the last 24 hours and down -4.70% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Previous Close:

$0.933

Open:

$0.9101

24h Volume:

839.59K

Relative Volume:

1.18

Market Cap:

$112.22M

Revenue:

$140.46M

Net Income/Loss:

$-146.34M

P/E Ratio:

-0.6407

EPS:

-1.32

Net Cash Flow:

$-117.73M

1W Performance:

-0.21%

1M Performance:

-4.70%

6M Performance:

-25.16%

1Y Performance:

-4.98%

1-Day Range:

$0.8457

$0.9324

1-Week Range:

$0.8402

$1.13

52-Week Range:

$0.6174

$1.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

325

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

12:45 PM

Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - Yahoo Finance

12:45 PM

08:51 AM

Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle

08:51 AM

08:40 AM

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

08:40 AM

08:22 AM